Proprietary BIP portfolio discontinued
For further information and about the discontinuation, please contact us here.
BIP Central Venous Catheter
- Central Venous Catheter with Bactiguard’s infection prevention technology
- Reduces the risk of catheter-related infections1
- Has shown very good blood compatibility2
- No increased risk of thrombosis or hemolysis compared to uncoated CVCs3
- Swedish patented technology
Catheter-related bloodstream infection
Catheter related bloodstream infection is one of the most common healthcare associated infections4 and at the same time one of the most expensive and fatal complications associated with central venous catheters. The catheter surface attracts microbes, which colonize it and may develop a biofilm leading to infection.
Bactiguard’s infection prevention central venous catheter, BIP CVC, with Bactiguard coating reduces microbial adhesion, which decreases the risk of biofilm formation and infection.
Reduces microbial adhesion on the catheter
The Bactiguard technology is based on a very thin noble metal alloy coating, firmly attached to the catheter surface. When in contact with fluids (blood), the noble metals create a galvanic effect which reduces microbial adhesion. This means that fewer bacteria adhere to the catheter surface, which reduces the risk of biofilm formation leading to infection.
Safe to use
Bactiguard’s ultra-thin coating contains only very small amounts of noble metals, all well below established safety limits. Unlike traditional coatings that rely on releasing bacteria-killing substances such as high concentrations of silver ions, chlorhexidine, or antibiotics, Bactiguard’s coating is firmly attached and does not release any toxic or pharmacological quantities.
The technology is well proven; over 100,000 patients have been included in clinical trials and more than 245 million Bactiguard coated products used in patient without a single adverse event reported related to the coating
Excellent blood compatibility
Thrombotic complications are common and lead to obstruction of blood flow and catheter dysfunction. The catheter may need to be exchanged and the risk of infection increases, leading to increased costs of care. Catheter-related thrombosis leads to increased morbidity and may increase mortality due to embolic events.5
The Bactiguard coating has shown very good blood compatibility.2 In addition, clinical data show that there is no increased risk of thrombosis or haemolysis when using BIP CVC when compared to uncoated CVCs.3
Provides cost savings
The Bactiguard technology is associated with lower length of hospital stay costs, lower treatment costs and improved patient quality of life.6
Product details
The BIP CVC is used for administration of drugs and intravenous solutions, sample blood and for blood pressure monitoring. It is made of polyurethane, coated with the Bactiguard coating and approved for use up to 30 days.
BIP CVC is available in many different sizes, lengths and number of lumens (1-4 lumens), as well as with a straight needle, Y-valve needle or Raulerson syringe.
References:
1. Goldschmidt H, et al. 1995; Prevention of catheter-related infections by silver coated central venous catheters in oncological patients. Zentralbl Bakteriol 1995 Dec;283(2):215-223.
2. Vafa Homann et al. 2015; J. Improved ex vivo blood compatibility of central venous catheter with noble metal alloy coating. J Biomed Mater Res B Appl Biomater. 2016;104(7):1359–1365. doi:10.1002/jbm.b.33403.
3. Harter et al, Cancer. 94 (1):245–251 (2002).
4. Klevens RM et al. Estimating healthcare associated infections and deaths in U.S. hospitals, 2002 Public Health Rep. 2007 Mar-Apr;122(2):160–6.
5. Wall et al. Catheter-related thrombosis: A practical approach, Journal of the Intensive Care Society 2016, Vol. 17(2) 160–167
6. Saint S. et al. Arch Intern Med. 2000;160:2670–2675.